Ligustrazine (Standard)
Based on 1 Customer Validation
Ligustrazine (Standard) (Chuanxiongzine (Standard)) is the analytical standard of Ligustrazine (HY-N0264). This product is intended for research and analytical applications. Ligustrazine (Chuanxiongzine) is an orally active, blood-brain barrier-permeable alkaloid. It can be isolated from Ligusticum striatum DC. Ligustrazine reduces ROS, upregulates the levels of p-Akt/Akt and p-eNOS/eNOS, and decreases ALT and AST. It inhibits glutamate excitotoxicity, calcium overload, oxidative stress, ischemia-reperfusion injury and atherosclerotic plaque progression, enhances synaptic plasticity, and improves neurological function, cerebral infarct volume and brain water content. Ligustrazine possesses anti-inflammatory, antioxidant, lipid-lowering, endothelial protective and hepatoprotective activities. It can be used in studies related to ischemic stroke, cerebral ischemia-reperfusion injury and atherosclerosis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.99%
- CAS No.: 1124-11-4
- Formule: C8H12N2
- Masse moléculaire:136.19
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Product Information
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 1124-11-4
-
Appearance Solid
-
Masse moléculaire 136.19
-
Formule C8H12N2
-
Color White to off-white
-
SMILES
CC1=C(C)N=C(C)C(C)=N1
-
Synonyms
Chuanxiongzine (Standard); Tetramethylpyrazine (Standard)
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Wang Z, et al. The protective effects of ligustrazine on ischemic stroke: a systematic review and meta-analysis of preclinical evidence and possible mechanisms. Front Pharmacol. 2024;15:1373663. Published 2024 Mar 13. [Content Brief]
[2]. Ding Y, et al. The protective effect of ligustrazine on rats with cerebral ischemia-reperfusion injury via activating PI3K/Akt pathway. Hum Exp Toxicol. 2019;38(10):1168-1177. [Content Brief]
[3]. Jiang F, et al. Ligustrazine improves atherosclerosis in rat via attenuation of oxidative stress. Pharm Biol. 2011;49(8):856-863. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
- Ligustrazine (Standard)
- 1124-11-4
- Chuanxiongzine (Standard)
- Tetramethylpyrazine (Standard)
- Reference Standards
- Reactive Oxygen Species (ROS)
- Akt
- NO Synthase
- Aminotransferases (Transaminases)
- PI3K/Akt
- human amniotic epithelial cells
- Kunming mouse
- MMP-9
- caspase-3
- C57BL/6 mouse
- claudin-5
- JAK/STAT
- calcium channels
- Wistar rats
- Inhibitor
- inhibitor
- inhibit